Festival of Biologics 2025

Summary:

The arena of therapeutic antibodies is led by monoclonal antibodies (mAbs), bispecifics (BsAbs) and antibody drug conjugates (ADCs) with more complex Fc-containing formats currently gaining clinical traction. Antigen targeting remains the focus of candidate selection, however, Fc-mediated functions of antibodies significantly impact clinical efficacy and safety. Most developmental pipelines only assess Fc functions mediated by a narrow set of effectors, namely, NK cells (ADCC), monocytes (ADCP), and complement (CDC), but do not consider other immune effectors such as macrophages, neutrophils, basophils, eosinophils, dendritic cells, and platelets. A comprehensive assessment of Fc mediated functions can enable data-driven lead selection and optimization to advance the most promising candidates into the clinic with confidence.